MANAGEMENT OF PULMONARY HYPERTENSION AT CHILDREN AND ADOLESCENTS

Alina-Costina Luca, Mariana Pagute and Constantin Iordache
Additional contact information
Alina-Costina Luca: “Grigore T.Popa” University of Medicine and Pharmacy
Mariana Pagute: “St. Mary” Emergency Hospital for Children
Constantin Iordache: “Grigore T.Popa” University of Medicine and Pharmacy

Management Intercultural, 2016, issue 36, 203-208

Abstract: Pulmonary arterial hypertension (PAH) is considered a rare disease in the pediatric population, is idiopathic or associated with congenital heart disease, it is rarely associated with connective tissue disease, it represents an important cause of morbidity and mortality. According to data from the Netherlands, the incidence and prevalence is 0.7 and 4.4 for idiopathic PAH and 2.2 and 15.6 for PAH associated with congenital heart disease, cases per one million children. Selective vasodilator therapy has significantly improved the prognosis and life expectancy for affected children. This article addresses current knowledge about PAH in children, reviewing diagnostic criteria and therapeutic management.

Keywords: Pulmonary Arterial Hypertension; Congenital Heart Disease; Vasodilators; Children (search for similar items in EconPapers)
JEL-codes: I10 I13 I19 (search for similar items in EconPapers)
Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
http://seaopenresearch.eu/Journals/articles/MI_36_29.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cmj:interc:y:2016:i:36:p:203-208

Access Statistics for this article

Management Intercultural is currently edited by Romanian Foundation for Business Intelligence

More articles in Management Intercultural from Romanian Foundation for Business Intelligence, Editorial Department
Bibliographic data for series maintained by Serghie Dan ().